Radionuclide Alpha Particle Radiotherapy for Deep Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional radiotherapy methods, such as photodynamic therapy and external beam radiation, face limitations in penetrating deep tissues and effectively targeting tumors, especially for cancers that have metastasized or are located beneath the skin, due to the limited range of gamma and beta rays and the inefficiency of alpha particles in delivering therapeutic doses to internal tumors.
Innovation Solution
A method and device utilizing decay chain nuclei of radionuclides like Radium-223, Radium-224, Radon-219, and Radon-220 to administer alpha particles directly to tumors, either by positioning radionuclides in proximity to or within the tumor for a predetermined time to deliver a therapeutic dose, followed by removal or complete decay, allowing for localized and efficient tumor destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of moving object
If external beam radiation or gamma rays are used for radiotherapy, then the radiation can penetrate deep tissues, but the efficiency of delivering therapeutic doses to internal tumors is insufficient due to limited penetration depth and energy distribution
Solution Approach 1:
The patent uses alpha-emitting radionuclides (Radium-223, Radium-224, Radon-219, Radon-220) as intermediary carriers that deliver alpha particles directly to tumor cells. These radionuclides are positioned in proximity to or within the tumor, serving as a mediator between the radiation source and target, enabling efficient local dose delivery while avoiding the penetration limitations of external beam radiation
Solution Approach 2:
The invention applies local quality by concentrating alpha particle emission specifically at the tumor site through radionuclide placement. The decay chain nuclei are localized to deliver high-LET radiation only where needed, creating a locally optimized treatment that maximizes therapeutic effect on tumor cells while sparing surrounding healthy tissues from unnecessary radiation exposure
2Productivity
If alpha particles are used for radiotherapy, then the cell killing efficiency is extremely high, but the range in human tissue is less than 0.1 millimeter limiting their use to surface tumors
Solution Approach 1:
The patent employs alpha-emitting radionuclides as intermediaries that bridge the gap between the short range of alpha particles and deep-seated tumors. By positioning the radionuclide source within or adjacent to the tumor, the system delivers the full benefit of alpha particle cell-killing efficiency to internal tumors that would otherwise be inaccessible due to the sub-millimeter penetration range
Solution Approach 2:
The invention transitions from external to internal radiation delivery by placing radionuclides within the tumor microenvironment. This dimensional shift from external beam to internal source enables alpha particles to reach their full therapeutic potential by eliminating the need to penetrate through overlying healthy tissues, effectively converting a surface-only treatment into a deep-tissue capable therapy
3Productivity
If a large amount of light radiation is delivered to activate photosensitive agents in PDT, then the photosensitive drug can destroy abnormal tissue, but the penetration depth is limited to three or less centimeters of tissue
Solution Approach 1:
The patent replaces the optical activation mechanism of PDT with a radioactive decay mechanism. Instead of using light-activated photosensitive agents that are limited by optical penetration depth, the invention uses alpha-emitting radionuclides whose decay products (alpha particles and decay chain nuclei) directly damage tumor DNA. This substitution of the activation mechanism eliminates the penetration depth limitation inherent in light-based therapies
Solution Approach 2:
The invention changes the fundamental parameter of energy delivery from optical photons to alpha particles. This parameter change transforms the therapy from being light-penetration-limited to being radionuclide placement-dependent, enabling treatment of deep-seated tumors by simply repositioning the source internally rather than being constrained by the three-centimeter optical penetration barrier
4Length of moving object
If external irradiation is used to treat internal tumors, then the radiation source can reach the tumor, but healthy regions surrounding the tumor are adversely affected
Solution Approach 1:
The patent applies local quality by concentrating the radiation source within or adjacent to the tumor. The radionuclide placement ensures that alpha particles and decay chain nuclei are generated in immediate proximity to tumor cells, creating a highly localized treatment zone. This localizes the harmful effects to the tumor site while sparing surrounding healthy tissues from the high-LET radiation that would otherwise be distributed throughout the irradiation path in external beam therapy
Solution Approach 2:
The radionuclide serves as an intermediary that delivers radiation directly to the tumor from within its microenvironment. This intermediary approach replaces external beam delivery, allowing the radiation source to be positioned strategically at the tumor site to maximize local effect while minimizing exposure to surrounding healthy tissues through precise radionuclide placement and retention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the delivery of a therapeutic dose of alpha particles to tumors, both superficial and deep-seated, with minimal damage to surrounding healthy tissue, by using radionuclides that emit alpha particles and their decay chain nuclei, thereby enhancing the effectiveness of radiotherapy for various cancer types.
Implementation Method 1
positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period, the predetermined amount and the predetermined time period selected sufficient for the radionuclide to administer a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor
Data Source
AI summary
A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor.